RedHawk (SNDD) 10-K 15 Oct 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2019	Oct. 08, 2019	Dec. 31, 2018
Document And Entity Information
Entity Registrant Name	RedHawk Holdings Corp.
Entity Central Index Key	0001353406
Document Type	10-K
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Incorporation, State or Country Code	NV
Entity File Number	000-54323
Title of 12(g) Security	Common Stock, $0.001 par value
Trading Symbol	IDNG
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		905,759,097
Entity Public Float			$ 629,993
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Current Assets:
Cash	$ 1,648	$ 19,034
Certificate of deposit	100,374	100,073
Receivables		17,946
Inventory, at cost	181,227	218,538
Prepaid expenses	148,115	34,926
Total Current Assets	431,364	390,517
Property and Improvements:
Land	110,000	110,000
Building and improvements	670,000	670,000
Property and Improvements Before Depreciation	780,000	780,000
Less, accumulated depreciation	(112,479)	(81,146)
Total Property and Improvement	667,521	698,854
Other Assets:
Investment in real estate limited partnership	257,173	625,000
Other assets	104,283	85,783
Intangible assets, net of amortization of $404,946 and $334,962,respectively	848,992	415,163
Total Other Assets	1,210,448	1,125,946
Total Assets	2,309,333	2,215,317
Current Liabilities:
Accounts payable and accrued liabilities	899,685	774,568
Current maturities of long-term debt	184,585	9,450
Lines of credit	253,219	100,553
Insurance notes payable	136,859	7,786
Total Current Liabilities	1,474,348	892,357
Non-current Liabilities
Due to related parties	180,250	118,924
Other non-current liabilities	703,750
Real estate note payable, net of current maturities	224,097	233,772
Convertible notes payable, net of $49,241 and $60,420 in deferred loan costs and unamortized beneficial conversion of $0 and $59,042, respectively	392,304	861,189
Total Long-Term Debt	1,500,401	1,213,885
Total Liabilities	2,974,749	2,106,242
Commitments and Contingencies
Stockholders' Equity (Deficit):
Common Stock, par value of $0.001 per share, 2,000,000,000 and 1,000,000,000 authorized shares, respectively, and 1,034,340,037 and 398,410,762 issued, respectively	1,034,340	398,411
Additional paid-in capital	51,811	1,311,076
Accumulated other comprehensive loss	2,735
Accumulated deficit	(5,674,436)	(4,302,291)
Total Stockholders' Equity (Deficit) Before Treasury Stock	(85,058)	474,427
Less, Treasury stock 201,548,643 and 18,021,535 shares, respectively, at cost	(580,358)	(365,352)
Total Stockholders' Equity (Deficit)	(665,416)	109,075
Total Liabilities and Stockholders' Equity (Deficit)	2,309,333	2,215,317
5% Series A Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, value	3,021,453	1,659,889
5% Series B Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, value	$ 1,479,039	$ 1,407,342

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Amortization of intangible assets	$ 404,946	$ 334,962
Deferred loan costs, noncurrent	49,241	60,420
Unamortized beneficial conversion	$ 0	$ 59,042
Preferred stock, authorized	5,000	5,000
Preferred stock, issued	4,000	4,000
Preferred stock, outstanding	4,000	4,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	2,000,000,000	1,000,000,000
Common stock, issued	1,034,340,037	398,410,762
Treasury stock	201,548,643	18,021,535
5% Series A Preferred Stock [Member]
Preferred stock, value (in dollars per share)	$ 1,098.71	$ 1,127
Preferred stock, designated	2,750	2,750
Preferred stock, issued	2,750	1,473
Preferred stock, outstanding	2,750	1,473
5% Series B Preferred Stock [Member]
Preferred stock, value (in dollars per share)	$ 118,323	$ 1,126
Preferred stock, designated	1,250	1,250
Preferred stock, issued	1,250	1,250
Preferred stock, outstanding	1,250	1,250

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues	$ 129,006	$ 275,845
Operating Expenses:
Costs of goods sold	55,553	181,763
Sales and marketing expenses	15,820	108,758
Professional fees	261,476	48,464
Operating expenses	104,720	33,718
Depreciation and amortization	101,317	138,554
General and administrative	252,063	202,252
Total Operating Expenses	790,949	713,509
Net Loss from Operations	(661,943)	(437,664)
Other Income (Expense):
Amortization of discount on convertible debentures	(21,800)	(21,800)
Settlement loss	(471,880)	(62,425)
Litigation expense	(127,860)	(250,000)
Gain on extinguishment of debt	375,287
Interest expense	(307,688)	(138,173)
Total Other Income (Expense)	(553,941)	(472,398)
Net Loss	(1,215,884)	(910,062)
Other comprehensive income:
Effect of foreign currency translation	2,735
Total Other comprehensive income	2,735
Comprehensive Loss	(1,213,149)	(910,062)
Preferred Stock Dividends	(156,261)	(148,686)
Comprehensive Loss Available for Common Stockholders	$ (1,369,410)	$ (1,058,748)
Net Loss Per Share
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted Average Shares Outstanding
Basic (in shares)	551,650,769	357,250,050
Diluted (in shares)	551,650,769	357,250,050

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,215,884)	$ (910,062)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangibles	69,984	91,554
Amortization of discount on convertible debentures	21,800	21,800
Amortization of deferred loan costs	61,763	49,989
Depreciation	31,333	47,000
Other non-cash expenses	123,308	35,417
Non-cash interest expense	63,124	30,271
Non-cash settlement loss	221,524	62,475
Gain on extinguishment of debt	(375,287)
Changes in operating assets and liabilities:
Accounts receivable	17,266	175,354
Inventory	30,278	151,147
Prepaid expense and other assets	(133,782)	(75,783)
Accounts payable and accrued liabilities	140,911	(90,430)
Net Cash Used in Operating Activities	(943,662)	(411,268)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from distribution from limited liability partnership	367,827
Certificate of deposit purchase		(100,073)
Purchase of license	(51,250)
Net Cash Provided by (Used in) Investing Activities	316,577	(100,073)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related parties, net	61,326	54,674
Proceeds from issuance of convertible notes	384,622	473,000
Proceeds from issuance of stock		19,350
Costs related to debt for equity conversions	(10,300)
Deferred loan costs	(56,002)	(67,495)
Proceeds from long-term debt	180,000
Purchase of treasury stock	(78,566)
Proceeds from short-term debt	152,666	100,553
Net proceeds from insurance notes payable	129,073	561
Principal payments on convertible notes	(143,478)	(88,000)
Principal payments on long-term debt	(9,122)	(8,030)
Net Cash Provided by Financing Activities	610,219	484,613
Effect of exchange rate on cash	(520)	(8,177)
Decrease in cash	(17,386)	(34,905)
Cash, Beginning of Period	19,034	53,939
Cash, End of Period	1,648	19,034
Non-Cash Investing and Financing Activities:
Preferred stock dividends paid-in-kind	156,261	148,686
Conversion of debt to common stock	806,132	20,760
Increase in liabilities related to license agreement acquisition	403,750
Common stock issued related to license agreement acquisition	17,500
Convertible debt issued in exchange for treasury shares		29,250
Reduction in equity from share exchange to acquire 100% in EcoGen Europe Ltd.		311,590
Preferred stock exchanged for common stock	1,277,000
Supplemental Disclosures:
Interest paid in cash	30,972	39,715
Income tax paid

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical)	12 Months Ended
	Jun. 30, 2019
EcoGen Europe Limited ("EcoGen") [Member]
Reduction in equity from share exchange percentage	100.00%

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($)	5% Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	ACCUMULATED OTHER COMPREHENSIVE LOSS [Member]	Noncontrolling Interest [Member]	ACCUMULATED DEFICIT [Member]	TREASURY STOCK [Member]	Total
Balance at beginning at Jun. 30, 2017	$ 1,579,425	$ 1,339,120	$ 379,071	$ 1,254,889		$ 62,500	$ (3,243,543)	$ (76,102)	$ 1,295,360
Balance at beginning (in shares) at Jun. 30, 2017	1,473	1,250	379,070,562					18,021,535
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Preferred stock dividends declared	$ 80,464	$ 68,222					(148,686)
Sale of registered shares
Sale of registered shares (in shares)
Stock grants			$ 5,000	30,417					35,417
Stock grants (in shares)			5,000,000
Non-controlling interests acquired						(62,500)		$ (260,000)	(322,500)
Non-controlling interests acquired (in shares)								10,000,000
Conversion			$ 6,890	3,970					10,860
Conversion (in shares)			6,890,200
Shares sold by Beechwood			$ 7,450	21,800
Shares sold by Beechwood (in shares)			7,450,000
Net loss							(910,062)		(910,062)
Balance at ending at Jun. 30, 2018	$ 1,659,889	$ 1,407,342	$ 398,411	1,311,076			(4,302,291)	$ (365,352)	109,075
Balance at ending (in shares) at Jun. 30, 2018	1,473	1,250	398,410,762					35,471,535
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Preferred stock dividends declared	$ 84,564	$ 71,697					(156,261)
Stock grants			$ 67,400	55,909					123,309
Stock grants (in shares)			67,400,000
Conversion			$ 568,529	(174,614)					393,915
Conversion (in shares)			568,529,275
Shares acquired	$ 1,277,000			(1,140,560)				$ (215,006)	(78,566)
Shares acquired (in shares)	1,277							166,077,108
Net loss					2,735		(1,215,884)		(1,213,149)
Balance at ending at Jun. 30, 2019	$ 3,021,453	$ 1,479,039	$ 1,034,340	$ 51,811	$ 2,735		$ (5,674,436)	$ (580,358)	$ (665,416)
Balance at ending (in shares) at Jun. 30, 2019	2,750	1,250	1,034,340,037					201,548,643

NATURE OF OPERATIONS AND CONTIN

NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS	12 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS	1. NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS RedHawk Holdings Corp. was incorporated in the State of Nevada on November 30, 2005 under the name “Oliver Creek Resources Inc.” Effective August 12, 2008, we changed our name from “Oliver Creek Resources Inc.” to “Independence Energy Corp.” Effective October 13, 2015, by vote of a majority of the Company’s stockholders, the Company’s name was changed from “Independence Energy Corp.” to “RedHawk Holdings Corp.” Currently, we are a diversified holding company which, through our subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the SANDD™ Insulin Needle Destruction Unit (formerly known as the Disintegrator™), the Carotid Artery Digital Non-Contact Thermometer and Zonis ® Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will be able to continue as a going concern without further financing. The Company must continue to realize its assets to discharge its liabilities in the normal course of business. The Company has generated limited revenues to date and has never paid any dividends on its common stock and is unlikely to pay any common stock dividends or generate significant earnings in the immediate or foreseeable future. For the year ended June 30, 2019, the Company had revenues of $129,006, a consolidated net loss of $1,215,884 and cash used in operating activities of $943,662. For the year ended June 30, 2018, the Company had $275,845 in revenue, a consolidated net loss of $910,062 and cash of $411,268 used in operating activities. As of June 30, 2019, the Company had cash of $1,648 and a certificate of deposit of $100,374, a working capital deficit of $1,042,984 and an accumulated deficit of $5,674,436. The continuation of the Company as a going concern is still dependent upon the continued financial support from its stockholders, the ability to raise equity or debt financing, cash proceeds from the sale of assets and the attainment of profitable operations from the Company’s businesses in order to discharge its obligations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements of the Company as of June 30, 2019 and 2018 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (which we refer to as “GAAP”) pursuant to the rules and regulations of the SEC. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost. Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of investments, intangible assets, and long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued ASU 2014-19, Revenue from Contracts with Customers Revenue Recognition, for additional information. We derive revenue from several types of activities – medical device sales, branded generic pharmaceutical sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Through our United Kingdom based subsidiary, we manufacture, and market, branded generic pharmaceuticals, and certain other generic pharmaceuticals known as “specials”. Our real estate leasing revenues are from certain commercial properties under lease. The financial service revenue is from brokerage services. The Company offers customer discounts in certain cases. Such discounts are estimated at time of product sale and revenues are reduced for such discounts at the time of the sale. Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2019 or 2018. Accounts Receivable Accounts receivables are amounts due from customers of our pharmaceutical, medical device and financial services divisions. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of June 30, 2019 and June 30, 2018. Inventory Inventory consist of purchased thermometers, an advanced bleeding control, non-compression hemostasis, a patented antimicrobial ionic silver calcium catheter dressing, needle destruction devices and certain branded generic pharmaceuticals held for resale. All inventories are stated at the lower of cost or net realizable value utilizing the first-in, first-out method. Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight-line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 to 30 years. Building improvements are depreciated over a useful life of 5 to 10 years. During the year ended June 30, 2017, we decided to sell our Louisiana real estate holdings, which includes our former corporate headquarters on Chemin Metairie Road in Youngsville, Louisiana and a property on Jefferson Street in Lafayette, Louisiana that we are leasing to a third party. As a result of that decision, the net book value of those properties along with related mortgage notes were reflected as assets and liabilities held for sale in the June 30, 2017 balance sheet. At that time, we also ceased depreciating such assets. All such amounts are included in the land and hospitality segment. A sale of these properties did not occur in the fiscal year ended June 30, 2018 and, as such, the Company returned these properties to assets held for use and depreciation expenses had been recorded in 2018 for the period the properties were included in assets held for sale. Based on the present real estate market and discussions with brokers, no impairment of the recorded amounts has occurred as of June 30, 2019. Effective July 1, 2017, the Chemin Metairie Road property was leased under a one-year term at a rent of $1,500 per month. The lessee had an option to purchase the property during the lease for the lesser of $300,000 or the average of two independent appraisals. On June 30, 2018, the tenant did not exercise his option to purchase the property. The Company has returned the property to service and currently uses this property as offices for our real estate management unit. Effective August 1, 2017, the tenant that leases the Jefferson Street property renewed that lease through December 31, 2022 at a rent of $3,250 per month. Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes, Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, At June 30, 2019, including accrued but unpaid interest, there were $135,044 in Fixed Rate Convertible notes outstanding of which $76,213 were converted subsequent to June 30, 2019. The remaining Fixed Rate Convertible notes are convertible into 3,922,066 shares upon conversion of the Fixed Rate Convertible notes. There are $256,500 in convertible notes that are convertible at a variable conversion rate and not included in the issuable share amount in the preceding sentence. Also, at June 30, 2019, including accrued but unpaid dividends, there were potentially 201,430,200 shares issuable upon the conversion of the Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 147,903,900 shares issuable upon the conversion of the Series B Preferred stock. The shares to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive. Subsequent to June 30, 2019, we issued new Fixed Rate Convertible notes in the amount of $500,000. With the proceeds we paid off convertible notes outstanding as of June 30, 2019 in the amount of approximately $217,000, plus accrued interest, and had $41,250 of convertible notes outstanding as of June 30, 2019 that converted into 41,250,000 shares of Common Stock subsequent to June 30, 2019. Comprehensive Income (Loss) ASC 220, Comprehensive Income Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, debt, and amounts due to related parties. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Reclassification Certain amounts in prior periods have been reclassified to conform to the current year presentation. Leases In February 2016, the FASB issued ASU 2016-02, Leases

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	12 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	3. REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue Recognition Sales of pharmaceuticals and medical devices are recognized generally at the point in time when delivery occurs and title transfers to the buyer. Sales of pharmaceuticals and medical devices are usually collected within 90 days of the date of sale. As of June 30, 2019, we have distributorship and sales representative agreements in place with third parties who do not take ownership of products. Any costs incurred related to these agreements are considered to be sales and marketing expenses. We also earn rental income which is recognized over time as the tenant occupies the space and pays the rental amount. Rentals are paid at the beginning of the month covered by the lease. Disaggregation of Revenue For the years ended June 30, 2019 and 2018, a summary of our revenue on a disaggregated basis is as follows: 2019 2018 Sales of pharmaceuticals $ 71,792 $ 208,285 Sales of medical devices $ 12,705 $ 400 Rental revenue $ 44,509 $ 67,160 $ 129,006 $ 275,845 Transaction Prices In some cases, we may offer discounts to customers. In such cases, we reduce the recorded revenue for such discounts. In the years ended June 30, 2019 and 2018, our revenues were reduced by $39,995 and $108,434, respectively, for such discounts.

OTHER ASSETS

OTHER ASSETS	12 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
OTHER ASSETS	4. OTHER ASSETS On December 31, 2015, RedHawk Land & Hospitality, LLC, a wholly-owned subsidiary of the Company, acquired from Beechwood Properties, LLC (“Beechwood”) 280,000 Class A Units (approximately a 2.0% membership interest) of fully paid, non-assessable units of limited liability company interest in Tower Hotel Fund 2013, LLC, a real estate development limited liability company formed in the state of Hawaii for acquisition, restoration and development of the Naniloa Hilo Resort in Hilo, Hawaii. The $625,000 purchase price was paid by the issuance of 625 shares of the Company’s Series A Preferred Stock. The purchase price was determined by an independent third-party valuation. Beechwood Properties, LLC is a real estate limited liability company owned and controlled by G. Darcy Klug, a stockholder and Chief Financial Officer and Chairman of the board of directors of the Company. This investment in real estate limited partnership is recorded at cost and the Company is not aware of any indicator of impairment as of June 30, 2019. It is not practicable for the Company to estimate fair value of this investment. We are also pursuing the sale of our remaining investment in the real estate limited partnership investment. During the year ended June 30, 2019, based on stability of operations of the underlying real estate property and recent valuations, the partnership refinanced the property. We received a distribution of approximately $370,000 from the real estate limited partnership following this refinancing. This distribution was recorded as a reduction of our investment in the limited partnership, which is recorded at cost. We are currently in negotiations to sell our interest in the partnership but we are uncertain if such a transaction will close prior to June 30, 2020. Thus, our investment is shown as a non-current asset as of June 30, 2019 in the accompanying consolidated balance sheet. On March 23, 2016, one of our wholly-owned subsidiaries, RedHawk Pharma UK Ltd (which we refer to herein as “Pharma”), initially acquired a 25% equity interest in EcoGen Europe Ltd (which we refer to as “EcoGen”) from Scarlett Pharma Ltd (which we refer to herein as “Scarlett”). On September 12, 2017 we completed a share transfer agreement wherein we increased our ownership in EcoGen to 75%. On December 19, 2017 we completed another share transfer agreement wherein we increased our ownership in EcoGen to 100%. In connection with the December share transfer the non-controlling interest was eliminated. Under the terms of an agreement we reached with Scarlett and its affiliate related to these share exchanges, they surrendered ten (10) million shares of RedHawk common stock and transferred to RedHawk approximately $300,000 of EcoGen preferred stock and other consideration. In exchange, RedHawk assumed approximately $370,000 of obligations due to EcoGen by Scarlett and its affiliates. The RedHawk Shares were originally issued to Scarlett in connection with the Company’s March 2016 investment of 25% into EcoGen. As of December 31, 2017, Pharma now owns approximately $635,000 of EcoGen’s preferred stock and 100% of EcoGen’s common stock. The exchange agreements also settled numerous outstanding disputes between the Company, Scarlett, Warwick and the noncontrolling owners of the Company. A non-cash settlement loss of $62,425 resulted and is included in our results for the year ended June 30, 2018. During the fiscal year ended June 30, 2017, we began to consolidate the accounts of EcoGen in our financial statements under the variable interest entity model. In the quarter ended September 30, 2017, we became the majority owner of EcoGen and as of December 31, 2017, we now own 100% of the common stock of EcoGen. As of June 30, 2019, we have approximately $385,207 ($317,567 net of accumulated amortization) in intangible assets related to licenses held by EcoGen. Such intangible assets are being amortized over an estimated useful life of 20 years. In September 2018, the Company acquired the exclusive license rights to certain medical device technology for $450,000, plus a broker’s fee of $17,500. Under the terms of the license agreement, the Company has paid $25,000 plus the first of a total twenty quarterly payments of $21,250. Any remaining payments become immediately payable upon the receipt of final approval by the FDA of devices related to the technology. Additionally, the Company will pay a consulting fee of $1,000 per month for sixty months. The broker’s fee was paid through the issuance of 14 million shares of the Company’s common stock. The quarterly payments have been suspended at the present time as the Company and the seller negotiate certain disputes related to representations made by the seller at the time the Company acquired the rights. The ultimate date and resolution of this negotiation cannot be estimated at this time. As a result, the Company has included all of the future payments under the original agreement as noncurrent in the accompanying June 30, 2019 consolidated balance sheet.

INSURANCE NOTE PAYABLE

INSURANCE NOTE PAYABLE	12 Months Ended
	Jun. 30, 2019
Loans Payable [Abstract]
INSURANCE NOTE PAYABLE	5. INSURANCE NOTE PAYABLE We finance a portion of our insurance premiums. At June 30, 2019, there was a $136,859 outstanding balance due on our premium finance agreements. The agreements have effective interest rates of 6.6% to 13.5%. The policies related to these premiums expire between April and June 2020.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS Effective December 1, 2016, the Company entered into a $250,000 Commercial Note Line of Credit (which we refer to as the “Line of Credit”) with a stockholder and officer of the Company to evidence prior indebtedness and provide for future borrowings. The advances are used to fund our operations. The Line of Credit accrues interest at 5% per annum and matures on March 31, 2020. At maturity, or in connection with a pre-payment, subject to the conditions set forth in the Line of Credit, the stockholder has the right to convert the amount outstanding (or the amount of the prepayment) into the Company’s Series A Preferred Stock at the par value of $1,000 per share. During the year ended June 30, 2017, $250,000 of the amounts loaned under this line of credit were converted to preferred stock. At June 30, 2019, the principal balance totaled $0. The amount is included in noncurrent liabilities based on the expectation that either the Line of Credit maturity date will be extended, the outstanding amount will be refinanced through other long-term debt, or the amount outstanding will be converted to preferred stock as allowed for in the agreement. This same stockholder and officer also holds $8,250 of 5% convertible notes, which mature in December 2020 and are convertible into common stock at a rate of $0.015 per share or 550,000 shares. In the year ended June 30, 2019, certain members of the board of directors and stockholders of the Company made $172,000 in interest free advances to the Company. Subsequent to June 30, 2019, $10,000 of these advances were repaid. The remaining advances are convertible into shares of the Company’s common stock at rates ranging from $0.0024 to $0.0050 or 49,250,000 shares. All of the above liabilities are included in Due to Related Parties in the accompanying consolidated balance sheet as of June 30, 2019. During the year ended June 30, 2017, EcoGen had sales to customers which are controlled by individuals which are shareholders of EcoGen and were the noncontrolling interests in our consolidated financial statements. These sales totaled $1,241,000 on a gross basis and had discounts of $968,000. A portion of these discounts were at levels that exceeded discounts offered to unaffiliated customers. During the quarter ended March 31, 2017, management of RedHawk and these noncontrolling shareholders of EcoGen reached an agreement whereby $370,000 of such discounts were to be considered an account receivable due to EcoGen by this affiliated customer. Subsequent to June 30, 2017, the Company assumed the obligations of these noncontrolling shareholders in connection with the share exchanges discussed in Note 3. A settlement loss of $62,425 was incurred as a result of this agreement. Beginning in the quarter ended March 31, 2017, certain members of management agreed to forgo management fees in consideration of the operating cash flow needs of the Company. There is not a set timeline to reinstitute such management fees. As of June 30, 2019 and 2018, $50,000 in such fees remain unpaid and are recorded in accounts payable and accrued liabilities in the accompanying balance sheet.

LONG-TERM DEBT, DEBENTURES AND

LONG-TERM DEBT, DEBENTURES AND LINES OF CREDIT	12 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
LONG-TERM DEBT, DEBENTURES AND LINES OF CREDIT	7. LONG-TERM DEBT, DEBENTURES AND LINES OF CREDIT On November 12, 2015, we acquired certain commercial real estate from a related party that is an entity controlled by a stockholder and officer of the Company for $480,000 consisting of $75,000 of land costs and $405,000 of buildings and improvements (see Note 3). The purchase price was paid through the assumption by the Company of $265,000 of long-term bank indebtedness (which we refer to as “Note”) plus the issuance of 215 shares of the Company’s newly designated Series A Preferred Stock. The purchase price also included the cost of specific security improvements requested by the lessee. The Note is dated November 13, 2015 and has a principal amount of $265,000. Monthly payments under the Note are $1,962 including interest accruing at a rate of 5.95% per annum. The Note matures in June 2021 and is secured by the commercial real estate, guarantees by the Company and its real estate subsidiary and the personal guarantee of a stockholder who is also an officer of the Company. In March 2016, we authorized the issuance of up to $1 million in principal amount of convertible promissory notes (which we refer to as the “Fixed Rate Convertible Notes”). The Fixed Rate Convertible Notes are secured by certain Company real estate holdings. The Fixed Rate Convertible Notes issued mature on March 15, 2021, the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share. Interest accrues at a rate of 5% per annum and is payable semi-annually. The Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Fixed Rate Convertible Notes. The Company may only issue the notice of its intent to redeem the Fixed Rate Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem. The holder of the Fixed Rate Convertible Notes has the right to convert all or any portion of the Fixed Rate Convertible Notes at the conversion price at any time prior to redemption. During the year ended June 30, 2019, concurrent with the execution of the Exchange Agreement more fully described in Note 9, holders of $515,247 aggregate principal amount of the Company’s 5% convertible promissory notes (“Notes”), including accrued interest, converted their Notes into 103,132,226 shares of Common Stock. At June 30, 2019, there were approximately $135,000 of Fixed Rate Convertible Notes outstanding, of which $76,068 of Notes was converted into 15,213,646 shares of Common Stock subsequent to June 30, 2019. The remaining $50,000 of Fixed Rate Convertible Notes (plus accrued interest) are convertible into our common stock at a conversion rate of $0.015 per share or 3,922,066 shares. During the years ended June 30, 2019 and 2018, we paid-in-kind $29,294 and $29,943, respectively, of interest on these convertible notes. During the year ended June 30, 2019, we also issued $334,622 of convertible notes to third parties with variable conversion rates (“Variable Rate Convertible Notes”). The Variable Rate Convertible Notes mature at various dates between September and November 2019. We received, net of financing costs incurred, $289,622 in cash from the issuance of these notes. These Variable Rate Convertible Notes have interest accruing at rates ranging between 10% - 12%, and redemption. These notes issued to third parties have a variable conversion rate based on the price of the Company’s common stock. At June 30. 2019, $256,500 of the convertible notes are currently convertible into our Common Stock beginning in the quarter ending September 30, 2019. During the year ended June 30, 2019, holders of Variable Rate Convertible Notes converted $290,885 of notes, including accrued interest, into 465,397,050 shares of Common Stock. Subsequent to June 30, 2019, we also paid in full three convertible notes in the amount of $154,250 and notes totaling $41,250 were converted into equity. The Variable Rate Convertible Notes have maturity dates prior to June 30, 2020 and could be classified as a current liability. However, it is the Company’s expectation that we will either re-finance these convertible notes to longer terms or permit a limited amount of conversions. Therefore, we have classified these notes as noncurrent. If we do not re-finance these convertible notes to longer terms, however, the holders of the convertible notes have the option to convert these notes into equity or hold the convertible notes to maturity. Also, during the year ended June 30, 201, we issued $29,250 of convertible notes to our majority stockholder in exchange for 7,450,000 shares of our common stock. The note matures in December 2020 and is convertible into 1,950,000 shares, or $0.015 per share. (See Note 5.) In February 2018, we obtained a $100,000 line of credit from a bank. The line of credit matures in February 2021 and is collateralized by a $100,000 certificate of deposit at the bank. As of June 30, 2019, approximately $100,000 was drawn under the line of credit. The interest rate on the line of credit is 7.0% per annum. On March 12, 2019, we obtained a $180,000 real estate loan from a financial institution. The note matures on April 1, 2020 and is secured by certain real estate property and the personal guarantee of an officer and director of the Company. Interest only is payable monthly and accrues at an interest rate of 12%. In the quarter ended June 30, 2019, we entered into a series of credit financing arrangements from financing institutions by pledging future accounts receivable. The proceeds from these credit agreements were used to pay the initial amount due under the Schreiber settlement agreement. As of June 30, 2019, we had drawn approximately $150,000 under these agreements. Subsequent to June 30, 2019, we have paid off approximately $50,000 of these loans.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES On January 31, 2017, the Company and Beechwood filed suit against Daniel J. Schreiber (“Mr. Schreiber”) and the Daniel J. Schreiber Living Trust – Dtd 2/08/95 (“Schreiber Trust”) in the United States District Court for the Eastern District of Louisiana under Civil Action No. 2:2017cv819-B(3) (the “Louisiana Lawsuit”). Mr. Schreiber and the Schreiber Trust answered the Louisiana Lawsuit and counter-claimed against the Company and Beechwood and made additional claims against Mr. G. Darcy Klug (“Mr. Klug”) in the Louisiana Lawsuit. Mr. Klug is an officer and director of RedHawk and is sole owner of Beechwood. Mr. Klug also holds voting control of RedHawk. On April 24, 2017, Mr. Schreiber and the Schreiber Trust also filed suit against the Company, Mr. Klug and six (6) other defendants in the United States District Court for the Southern District of California under Civil Action No. 3:17-cv-00824-WQH-BLM which case was dismissed without prejudice on September 26, 2017 (the “California Lawsuit” and along with the Louisiana Lawsuit, the “Litigations”). On March 22, 2019, the parties to the Litigations have entered into a Settlement Agreement and General Release (“Settlement Agreement”) to resolve all issues arising out of the subject matter of the Litigation. In consideration of the mutual promises, covenants and conditions contained in the Settlement Agreement, the parties to the Litigation agreed that (i) Mr. Schreiber and the Schreiber Trust shall transfer all Company stock they presently own (52,377,108 common shares) to the Company and (ii) the Company shall (a) make to Mr. Schreiber and the Schreiber Trust a cash payment of Two Hundred Fifty Thousand and 00/100 Dollars (US$250,000.00) and (b) issue two Promissory Notes, each in the principal amount of Two Hundred Thousand and 00/100 Dollars (US$200,000.00), one of which shall be due and payable on or before September 6, 2020 and the other shall be due and payable on or before September 5, 2021. As a result of this Settlement Agreement, we have recorded a loss of $471,880 in the year ended June 30, 2019. Each Promissory Note shall be non-interest bearing, however each (i) shall bear a $15,000 late penalty if the principal amount is not repaid by the due date and (ii) shall bear interest at a rate of 18% per annum, from the issue date, if the principal is not repaid by the 30th date after the due date. Pursuant to a Security Agreement between the parties, Mr. Klug and Beechwood secured the Company’s obligations to the Schreiber Trust under the Settlement Agreement by granting first-priority security interests in (i) 1,000 shares of Mr. Klug’s Series B Preferred Company Stock; and 1,473 shares of Mr. Klug’s Series A Preferred Company Stock, and (ii) Beechwood’s interest in the Tower Hotels Fund 2014, LLC.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Jun. 30, 2019
Stockholders' Equity (Deficit):
STOCKHOLDERS' EQUITY	9. STOCKHOLDERS’ EQUITY On August 20, 2018, by a vote of the majority of our stockholders, we increased the number of our authorized shares from 1,000,000,000 to 2,000,000,000. Preferred Stock Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective November 12, 2015, 2,750 shares of our authorized Preferred Stock have been designated as Series A 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series A Preferred Stock”). The holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (which we refer to as “PIK”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After six months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends. Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective February 16, 2016, 1,250 shares of our authorized Preferred Stock have been designated as Series B 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series B Preferred Stock”). The holders of the Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series B Preferred Stock (which we refer to as “PIK”). Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted. After six months from issuance, each share of Series B Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.01, as adjusted for stock splits and dividends. During the year ended June 30, 2019 and 2018, we paid-in-kind $156,261 and $148,686, respectively, of related preferred stock dividends. Exchange Agreement On June 20, 2019, RedHawk Holdings Corp. entered into a Stock Exchange Agreement (“Exchange Agreement”) with Beechwood. G. Darcy Klug, the Company’s Chairman of the Board, Interim Chief Executive Officer and Chief Financial Officer, is the sole member and manager of Beechwood. Under the Exchange Agreement, the Company purchased from Beechwood 113,700,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), in exchange for 1,277 shares of the Company’s 5% Series A Preferred Stock and a Stock Purchase Warrant (“Warrant”) to acquire 113,508,450 shares of Common Stock at an exercise price of $0.005 per share (collectively, the “Transactions”). The Warrant expires June 20, 2029. Concurrent with the execution of the Exchange Agreement, holders of $574,250 aggregate principal amount of the Company’s 5% convertible promissory notes (“Notes”), including accrued interest, converted their Notes into 114,849,929 shares of Common Stock. The extinguishment of the notes and the related accrued interest for the shares of common stock resulted in a gain on extinguishment of $375,000 based on the closing price of the common stock as of the exchange date. Holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (“PIK dividends”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After six months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of Common Stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends. Warrants In conjunction with the Exchange Agreement, Beechwood was issued 113,508,450 warrants to purchase the Company’s common stock at a price of $0.005 per share. The warrants expire in June 2029 and are assignable.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES As of June 30, 2019, the Company had approximately $5 million of U.S. net operating losses (NOLs) carried forward to offset taxable income in future years. Approximately $4 million of this NOL will expire commencing in fiscal 2026 and run through 2038. The NOLs of approximately $1 million from the year ended June 30, 2019 has an indefinite carryforward period. As a result of the numerous common stock transactions that have occurred, the amount of these NOLs which is actually available to offset future income may be severely limited due to change-in-control tax provisions. The Company has not estimated the effect of such change-in-control limitation. The related deferred income tax asset of these NOLs, without consideration of any change-of-control limitation, was estimated to be approximately $750,000 as of June 30, 2019. As a result of the enactment of the Tax Cuts and Jobs Act (The Act) in December 31, 2017, the estimated deferred income tax asset related to U.S. NOL carry forwards is based on the reduced 21% corporate income tax rate. Due to our history of operating losses and the uncertainty surrounding the realization of the deferred tax assets in future years, our management has determined that it is more likely than not that the deferred tax assets will not be realized in future periods. Accordingly, the Company has recorded a valuation allowance against its net deferred tax assets. Thus, there is no net tax asset recorded as of June 30, 2019 or June 30, 2018 as a 100% valuation allowance has been established for any tax benefit. EcoGen also has a net operating loss as of June 30, 2019 and June 30, 2018 for which no deferred tax asset has been provided. Similarly, there is no income tax benefit recorded on the net loss of the Company for the years ended June 30, 2019 and 2018. The Company did not have any accumulated foreign earnings for which taxes were deferred and subject to the one-time transition tax under The Act. The Company accounts for interest and penalties relating to uncertain tax provisions in the current period statement of operations, as necessary. The Company’s tax years from inception are subject to examination. There are no income tax examinations currently in progress.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	11. SEGMENT INFORMATION SFAS No. 131, “Disclosures About Segments of an Enterprise and Related Information,” MEDICAL Year ended LAND & DEVICE & OTHER June 30, 2019 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 49,509 $ 84,497 $ — $ — $ 129,006 Operating loss $ (16,920 ) $ (75,375 ) $ (201 ) $ (569,447 ) $ (661,943 ) Interest expense $ 24,036 $ 527 $ — $ 283,125 $ 307,688 Depreciation and amortization $ 31,333 $ 69,984 $ — $ — $ 101,317 Identifiable assets $ 932,520 $ 163,857 $ 18,500 $ 1,194,456 $ 2,309,333 Year ended June 30, 2018 LAND & HOSPITALITY MEDICAL DEVICE & PHARMA OTHER SERVICES CORPORATE TOTAL Operating revenues $ 67,160 $ 208,685 $ — $ — 275,845 Operating loss (22,443 ) $ (217,174 ) $ (1,791 ) $ (196,256 ) $ (437,664 ) Interest expense $ 15,760 $ (5 ) $ — $ 122,418 $ 138,173 Depreciation and amortization $ 47,000 $ 91,554 $ — $ — $ 138,554 Identifiable assets $ 1,347,446 $ 702,516 $ 26 $ 165,329 $ 2,215,317

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company evaluates subsequent events through the time of our filing on the date we issue our financial statements, which was on October 15, 2019. The following are significant matters which occurred subsequent to June 30, 2019 and are not described fully in the notes to the financial statements: ● On September 16, 2019, the Company Securities Act Warrant Shares ● On September 30, 2019, a former officer and director of the Company agreed to convert approximately 250 shares of Series B Preferred Stock into 29,969,648 shares of the Company’s common stock.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements of the Company as of June 30, 2019 and 2018 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (which we refer to as “GAAP”) pursuant to the rules and regulations of the SEC
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost.
Use of Estimates	Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of investments, intangible assets, and long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued ASU 2014-19, Revenue from Contracts with Customers Revenue Recognition, for additional information. We derive revenue from several types of activities – medical device sales, branded generic pharmaceutical sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Through our United Kingdom based subsidiary, we manufacture, and market, branded generic pharmaceuticals, and certain other generic pharmaceuticals known as “specials”. Our real estate leasing revenues are from certain commercial properties under lease. The financial service revenue is from brokerage services. The Company offers customer discounts in certain cases. Such discounts are estimated at time of product sale and revenues are reduced for such discounts at the time of the sale.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2019 or 2018.
Accounts Receivable	Accounts Receivable Accounts receivables are amounts due from customers of our pharmaceutical, medical device and financial services divisions. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of June 30, 2019 and June 30, 2018.
Inventory	Inventory Inventory consist of purchased thermometers, an advanced bleeding control, non-compression hemostasis, a patented antimicrobial ionic silver calcium catheter dressing, needle destruction devices and certain branded generic pharmaceuticals held for resale. All inventories are stated at the lower of cost or net realizable value utilizing the first-in, first-out method.
Property and Improvements	Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight-line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 to 30 years. Building improvements are depreciated over a useful life of 5 to 10 years. During the year ended June 30, 2017, we decided to sell our Louisiana real estate holdings, which includes our former corporate headquarters on Chemin Metairie Road in Youngsville, Louisiana and a property on Jefferson Street in Lafayette, Louisiana that we are leasing to a third party. As a result of that decision, the net book value of those properties along with related mortgage notes were reflected as assets and liabilities held for sale in the June 30, 2017 balance sheet. At that time, we also ceased depreciating such assets. All such amounts are included in the land and hospitality segment. A sale of these properties did not occur in the fiscal year ended June 30, 2018 and, as such, the Company returned these properties to assets held for use and depreciation expenses had been recorded in 2018 for the period the properties were included in assets held for sale. Based on the present real estate market and discussions with brokers, no impairment of the recorded amounts has occurred as of June 30, 2019. Effective July 1, 2017, the Chemin Metairie Road property was leased under a one-year term at a rent of $1,500 per month. The lessee had an option to purchase the property during the lease for the lesser of $300,000 or the average of two independent appraisals. On June 30, 2018, the tenant did not exercise his option to purchase the property. The Company has returned the property to service and currently uses this property as offices for our real estate management unit. Effective August 1, 2017, the tenant that leases the Jefferson Street property renewed that lease through December 31, 2022 at a rent of $3,250 per month.
Income Taxes	Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes,
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, At June 30, 2019, including accrued but unpaid interest, there were $135,044 in Fixed Rate Convertible notes outstanding of which $76,213 were converted subsequent to June 30, 2019. The remaining Fixed Rate Convertible notes are convertible into 3,922,066 shares upon conversion of the Fixed Rate Convertible notes. There are $256,500 in convertible notes that are convertible at a variable conversion rate and not included in the issuable share amount in the preceding sentence. Also, at June 30, 2019, including accrued but unpaid dividends, there were potentially 201,430,200 shares issuable upon the conversion of the Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 147,903,900 shares issuable upon the conversion of the Series B Preferred stock. The shares to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive. Subsequent to June 30, 2019, we issued new Fixed Rate Convertible notes in the amount of $500,000. With the proceeds we paid off convertible notes outstanding as of June 30, 2019 in the amount of approximately $217,000, plus accrued interest, and had $41,250 of convertible notes outstanding as of June 30, 2019 that converted into 41,250,000 shares of Common Stock subsequent to June 30, 2019.
Comprehensive Loss	Comprehensive Income (Loss) ASC 220, Comprehensive Income
Financial Instruments	Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, debt, and amounts due to related parties. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current year presentation.
Leases	Leases In February 2016, the FASB issued ASU 2016-02, Leases

REVENUE FROM CONTRACTS WITH C_2

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	12 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of Revenue	For the years ended June 30, 2019 and 2018, a summary of our revenue on a disaggregated basis is as follows: 2019 2018 Sales of pharmaceuticals $ 71,792 $ 208,285 Sales of medical devices $ 12,705 $ 400 Rental revenue $ 44,509 $ 67,160 $ 129,006 $ 275,845

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Schedule of segment activity	These costs are not allocated to the operating segments when determining profit or loss. The following table reflects our segments as of June 30, 2019 and 2018 and for the twelve-month periods then ended. MEDICAL Year ended LAND & DEVICE & OTHER June 30, 2019 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 49,509 $ 84,497 $ — $ — $ 129,006 Operating loss $ (16,920 ) $ (75,375 ) $ (201 ) $ (569,447 ) $ (661,943 ) Interest expense $ 24,036 $ 527 $ — $ 283,125 $ 307,688 Depreciation and amortization $ 31,333 $ 69,984 $ — $ — $ 101,317 Identifiable assets $ 932,520 $ 163,857 $ 18,500 $ 1,194,456 $ 2,309,333 Year ended June 30, 2018 LAND & HOSPITALITY MEDICAL DEVICE & PHARMA OTHER SERVICES CORPORATE TOTAL Operating revenues $ 67,160 $ 208,685 $ — $ — 275,845 Operating loss (22,443 ) $ (217,174 ) $ (1,791 ) $ (196,256 ) $ (437,664 ) Interest expense $ 15,760 $ (5 ) $ — $ 122,418 $ 138,173 Depreciation and amortization $ 47,000 $ 91,554 $ — $ — $ 138,554 Identifiable assets $ 1,347,446 $ 702,516 $ 26 $ 165,329 $ 2,215,317

NATURE OF OPERATIONS AND CONT_2

NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues, net	$ 129,006	$ 275,845
Consolidated net loss	1,215,884	910,062
Net cash used in operating activities	943,662	411,268
Cash	1,648	19,034	$ 53,939
Certificate of deposit	100,374
Working capital	1,042,984
Accumulated deficit	$ (5,674,436)	$ (4,302,291)

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Jul. 02, 2019	Jun. 30, 2019
Warrant outstanding		113,508,450
Exercise price of warrants (in dollars per share)		$ 0.005
Incremental common shares issuable upon conversion of notes
Convertible notes, amount		$ 256,500
Aggregate principal amount		$ 135,000
Fixed rate convertible (in shares)		3,922,066
Subsequent Event [Member]
Aggregate principal amount	$ 76,068
Subsequent Event [Member] | Convertible Notes [Member]
Reversal accrued interest expense	217,000
Aggregate principal amount	500,000
Fixed rate convertible outstanding	76,213
Fixed Rate convertible	$ 41,250
Conversion of common stock issued	41,250,000
Minimum [Member]
Equity method ownership percentage		20.00%
Maximum [Member]
Equity method ownership percentage		50.00%
Building [Member] | Minimum [Member]
Useful life		20 years
Building [Member] | Maximum [Member]
Useful life		30 years
Building Improvements [Member] | Minimum [Member]
Useful life		5 years
Building Improvements [Member] | Maximum [Member]
Useful life		10 years
Chemin Metairie Road [Member]
Property lease term		1 year
Lease rent		$ 1,500
Frequency of periodic payment		Monthly
Lease rent subject to certain increase adjustments		$ 3,250
Payments to acquire property on lease		$ 300,000
Renewed lease term		Dec. 31, 2022
5% Series A Preferred Stock [Member]
Incremental common shares issuable upon conversion of preferred stock		201,430,200
Series B Preferred Stock [Member]
Incremental common shares issuable upon conversion of preferred stock		147,903,900

REVENUE FROM CONTRACTS WITH C_3

REVENUE FROM CONTRACTS WITH CUSTOMERS (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Rental revenue	$ 129,006	$ 275,845
Sales Of Pharmaceuticals [Member]
Rental revenue	71,792	208,285
Sales Of Medical Devices [Member]
Rental revenue	12,705	400
Rental revenue [Member]
Rental revenue	$ 44,509	$ 67,160

REVENUE FROM CONTRACTS WITH C_4

REVENUE FROM CONTRACTS WITH CUSTOMERS (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
Date of sale	90 days
Transaction prices	$ 39,995	$ 108,434

OTHER ASSETS (Details Narrative

OTHER ASSETS (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 19, 2017	Sep. 30, 2018	Dec. 31, 2015	Mar. 31, 2017	Jun. 30, 2019	Jun. 30, 2018	Sep. 12, 2017	Mar. 23, 2016
Intangible assets related to licenses						$ 848,992	$ 415,163
Chemin Metairie Road [Member]
Distribution received from real estate partnership						$ 370,000
License Agreement [Member]
Payments to acquire license rights			$ 21,250
Share Transfer Agreement [Member]
Consideration transferred amount		$ 300,000
Other consideration in exchange approximately		$ 370,000
Common Stock [Member]
Number of shares issued						67,400,000	5,000,000
Eco Gens Common Stock [Member] | Ownership [Member]
Percentage of ownership	100.00%
Eco Gens Preferred Stock [Member]
Amount ownes by pharma	$ 635,000
September 2018 [Member]
Settlement loss							$ 62,425
Payments to acquire license rights			25,000
September 2018 [Member] | Developed Technology Rights [Member]
Payments to acquire license rights			450,000
Consulting fee			1,000
Broker's fee			$ 17,500
September 2018 [Member] | Common Stock [Member]
Number of shares issued			1,400,000
EcoGen [Member]
Intangible assets related to licenses
Intangible assets, useful life						20 years
EcoGen [Member] | Maximum [Member]
Intangible assets related to licenses						$ 385,207
EcoGen [Member] | Minimum [Member]
Intangible assets related to licenses						$ 317,567
Scarlett Pharma Ltd (Scarlett) [Member]
Additional number of shares surrendered		10,000,000
EcoGen Europe Limited ("EcoGen") [Member]
Increased percentage of ownership		100.00%						75.00%
Settlement loss					$ (62,425)
EcoGen Europe Limited ("EcoGen") [Member] | Ownership [Member]
Percentage of ownership									25.00%
EcoGen Europe Limited ("EcoGen") [Member] | Ownership [Member] | March 2016 investment [Member]
Percentage of ownership		25.00%
Beechwood Properties, LLC [Member]
Number of units acquired				280,000
Percentage of membership interest acquired				2.00%
Consideration transferred amount				$ 625,000
Number of shares issued upon acquisition				625

INSURANCE NOTE PAYABLE (Details

INSURANCE NOTE PAYABLE (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Insurance notes payable	$ 136,859	$ 7,786
Description of the maturity date	Premiums expire between April and June 2020.
Minimum [Member]
Interest rates	6.60%
Maximum [Member]
Interest rates	13.50%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jul. 02, 2019	Feb. 28, 2018	Mar. 31, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Dec. 01, 2016
Line of credit interest rate		7.00%
Line of credit maturity date		Feb. 28, 2021
Line of credit converted into preferred stock				$ 393,915	$ 10,860
Due to related party				180,250	118,924
Accounts payable and accrued liabilities				50,000	$ 50,000
EcoGen Europe Limited ("EcoGen") [Member]
Total cost of sales						$ 1,241,000
Sales discount						968,000
Sales discount considered an accounts receivable			$ 370,000
Loss related to settlement			$ 62,425
Commercial Note Line of Credit [Member]
Due to related party				0
Stockholder and Officer [Member]
Commercial note line of credit				$ 8,250
Line of credit interest rate				5.00%
Line of credit maturity date				Dec. 31, 2020
Conversion of common stock issued				550,000
conversion price per share				$ 0.015
Board Of Directors And Stockholders [Member]
Conversion of common stock issued				49,250,000
Advances from stockholder				$ 172,000
Board Of Directors And Stockholders [Member] | Minimum [Member]
conversion price per share				$ 0.0024
Board Of Directors And Stockholders [Member] | Maximum [Member]
conversion price per share				$ 0.0050
Line of Credit [Member] | Stockholder and Officer [Member]
Commercial note line of credit							$ 250,000
Line of credit interest rate				5.00%
Line of credit maturity date				Mar. 31, 2020
Line of credit converted into preferred stock						$ 250,000
Line of Credit [Member] | 5% Series A Preferred Stock [Member] | Stockholder and Officer [Member]
Preferred stock, stated value (in dollars per share)				$ 1,000
Subsequent Event [Member]
Advances from stockholder	$ 10,000

LONG-TERM DEBT, DEBENTURES AN_2

LONG-TERM DEBT, DEBENTURES AND LINES OF CREDIT (Details Narrative) - USD ($)	Jul. 02, 2019	May 12, 2019	Feb. 28, 2018	Nov. 13, 2015	Nov. 12, 2015	Jun. 30, 2019	Jun. 30, 2018
Convertible promissory note principal						$ 135,000
Description of maturity						Premiums expire between April and June 2020.
Debt maturity date						Jun. 30, 2019
Convertible notes outstanding						$ 256,500
Net of financing costs						289,622
Interest paid in kind						29,294	$ 29,943
Line of credit outstanding			$ 100,000			253,219	100,553
Line of credit, maturity date			Feb. 28, 2021
Line of credit, collateral value			$ 100,000
Line of credit withdrawn						100,000
Line of credit interest rate			7.00%
Repayment of convertible debt						154,250
Amount of notes converted into equity						41,250
Accrued interest						50,000	$ 50,000
Real Estate Loan [Member] | Financial Institution [Member]
Convertible promissory note principal		$ 180,000
Convertible promissory notes interest rate		12.00%
Debt maturity date		Apr. 1, 2020
Line of credit withdrawn						$ 150,000
Subsequent Event [Member]
Convertible promissory note principal	$ 76,068
Subsequent Event [Member] | Real Estate Loan [Member] | Financial Institution [Member]
Line of credit, collateral value	$ 50,000
5% Series A Preferred Stock [Member]
Number of share issued					215
Land [Member]
Payment to acquired real estate from a related party					$ 75,000
Building and Improvements [Member]
Payment to acquired real estate from a related party					405,000
Stockholder and Officer [Member]
Payment to acquired real estate from a related party					480,000
Common stock conversion price | $ / shares						$ 0.015
Line of credit maximum borrowing capacity						$ 8,250
Line of credit, maturity date						Dec. 31, 2020
Line of credit interest rate						5.00%
Number of converted shares | shares						550,000
Common Stock [Member]
Number of shares issued on conversion						568,529,275	6,890,200
Number of share issued						67,400,000	5,000,000
Common Stock [Member] | Subsequent Event [Member]
Number of converted shares | shares	15,213,646
5% Convertible Promissory Notes [Member]
Convertible promissory note principal						$ 515,247
5% Convertible Promissory Notes [Member] | Common Stock [Member]
Accrued interest						103,132,226
Convertible Notes [Member]
Convertible promissory note principal				$ 265,000	$ 265,000
Debt instrument, monthly payment				$ 1,962
Frequency of periodic payment				Monthly
Convertible promissory notes interest rate				5.95%
Debt maturity date				Jun. 30, 2021
Description of collateral				Secured by the commercial real estate, guarantees by the Company and its real estate subsidiary and the personal guarantee of a stockholder who is also an officer of the Company.
Convertible Notes [Member] | Majority Stockholder [Member]
Description of maturity							December 2020
Common stock conversion price | $ / shares							$ 0.015
Number of converted shares | shares							7,450,000
Convertible debt conversion value							$ 29,250
Number of shares issued on conversion							1,950,000
Fixed Rate Convertible Notes [Member]
Convertible promissory note principal						$ 1,000,000
Convertible promissory notes interest rate						5.00%
Debt maturity date						Mar. 15, 2021
Common stock conversion price | $ / shares						$ 0.015	$ 0.015
Description of call feature						The Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Fixed Rate Convertible Notes. The Company may only issue the notice of its intent to redeem the Fixed Rate Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem.
Convertible notes outstanding
Number of converted shares | shares						3,922,066	3,922,066
Fixed Rate Convertible Notes [Member] | Common Stock [Member]
Convertible debt conversion value						$ 50,000
Variable Rate Convertible Notes [Member]
Convertible promissory note principal						$ 290,885
Variable Rate Convertible Notes [Member] | Minimum [Member]
Convertible promissory notes interest rate							10.00%
Variable Rate Convertible Notes [Member] | Maximum [Member]
Convertible promissory notes interest rate							12.00%
Variable Rate Convertible Notes [Member] | Third Parties [Member]
Description of maturity						September and November 2019
Net of financing costs						$ 334,622
Number of converted shares | shares
Convertible debt conversion value
Variable Rate Convertible Notes [Member] | Common Stock [Member]
Number of converted shares | shares						465,397,050

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Mar. 22, 2019	Nov. 12, 2015
5% Series A Preferred Stock [Member]
Number of shares issued		215
Settlement Agreement [Member]
Principal amount	$ 15,000
Settlement agreement terms	(i) Mr. Schreiber and the Schreiber Trust shall transfer all RedHawk stock they presently own (52,377,108 common shares) to RedHawk and (ii) Redhawk shall (a) make to Mr. Schreiber and the Schreiber Trust a cash payment of Two Hundred Fifty Thousand and 00/100 Dollars (US$250,000.00) and (b) issue two Promissory Notes, each in the principal amount of Two Hundred Thousand and 00/100 Dollars (US$200,000.00), one of which shall be due and payable on or before September 6, 2020 and the other shall be due and payable on or before September 5, 2021.
Settlement amount	$ 250,000
Settlement shares	52,377,108
Issue promissory notes	$ 200,000
Promissory note interest rate	18.00%
Settlement loss	$ 471,880
Security Agreement [Member] | 5% Series A Preferred Stock [Member]
Number of shares issued	1,473
Security Agreement [Member] | Series B Preferred Stock [Member]
Number of shares issued	1,000

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Feb. 16, 2016	Nov. 12, 2015	Jun. 20, 2019	Jun. 30, 2019	Jun. 30, 2018	Aug. 20, 2018
Preferred stock, authorized				5,000	5,000
Common stock, authorized				2,000,000,000	1,000,000,000	2,000,000,000
Dividends, preferred stock, paid-in-kind				$ 156,261	$ 148,686
Common Stock issued				1,034,340,037	398,410,762
Common Stock par value (in dollars per shares)				$ 0.001	$ 0.001
Warrant outstanding				113,508,450
Exercise price (in dollars per shares)				$ 0.005
Accrued interest				$ 50,000	$ 50,000
Convertible promissory note principal				135,000
Gain on extinguishment of debt				$ 375,287
Series B 5% Convertible Preferred Stock [Member]
Preferred stock, authorized	1,250
Preferred stock, stated value (in dollars per share)	$ 1,000
Description of preferred stock voting rights	Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share	$ 0.01
Series A 5% Convertible Preferred Stock [Member]
Preferred stock, authorized		2,750
Preferred stock, stated value (in dollars per share)		$ 1,000
Preferred stock cumulative dividend rate		5.00%
Description of preferred stock voting rights		Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share		$ 0.015
G. Darcy Klug [Member] | Stock Exchange Agreement [Member]
Common Stock issued			113,700,000
Common Stock par value (in dollars per shares)			$ 0.001
G. Darcy Klug [Member] | Warrant [Member] | Stock Exchange Agreement [Member]
Warrant outstanding			113,508,450
Exercise price (in dollars per shares)			$ 0.005
Warrant term			Jun. 20, 2029
Stock Exchange Agreement [Member] | G. Darcy Klug [Member] | 5% Series A Preferred Stock [Member]
Preferred stock cumulative dividend rate				5.00%
Number of shares converted			1,277
Discription of stock split				0.015 as adjusted for stock splits and dividends.
Stock Exchange Agreement [Member] | G. Darcy Klug [Member] | Warrant [Member]
Common Stock issued				113,508,450
Common Stock par value (in dollars per shares)				$ 0.005
Warrant term				Jun. 30, 2029
5% Convertible Promissory Notes [Member]
Convertible promissory note principal				$ 515,247
5% Convertible Promissory Notes [Member] | Common Stock [Member]
Accrued interest				103,132,226
Gain on extinguishment of debt				$ 375,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Net operating losses carryforwards	$ 5,000,000
Description income tax future year	Net operating losses (NOLs) carried forward to offset taxable income in future years which expire commencing in fiscal 2026 and run through 2038.
Operating losses future year	$ 4,000,000
Deferred tax assets operating loss carryforwards	$ 750,000
Reduced percentage of federal tax rate	21.00%
Deferred tax assets	$ 1,000,000
Percentage of deferred tax assets valuation allowance	100.00%	100.00%

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating revenues	$ 129,006	$ 275,845
Operating loss	(661,943)	(437,664)
Interest expense	307,688	138,173
Depreciation and amortization	101,317	138,554
Identifiable assets	2,309,333	2,215,317
Land & Hospitality [Member]
Operating revenues	49,509	67,160
Operating loss	(16,920)	(22,443)
Interest expense	24,036	15,760
Depreciation and amortization	31,333	47,000
Identifiable assets	932,520	1,347,446
Medical Device & Pharma [Member]
Operating revenues	84,497	208,685
Operating loss	(75,375)	(217,174)
Interest expense	527	(5)
Depreciation and amortization	69,984	91,554
Identifiable assets	163,857	702,516
Other Service [Member]
Operating revenues
Operating loss	(201)	(1,791)
Interest expense
Depreciation and amortization
Identifiable assets	18,500	26
Corporate [Member]
Operating revenues
Operating loss	(569,447)	(196,256)
Interest expense	283,125	122,418
Depreciation and amortization
Identifiable assets	$ 1,194,456	$ 165,329

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	12 Months Ended
	Jun. 30, 2019Number
Segment Reporting [Abstract]
Number of operating segments	3

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Sep. 30, 2019	Sep. 16, 2019	Jul. 02, 2019	Jun. 30, 2019	Jun. 30, 2018
Aggregate principal amount				$ 135,000
Common Stock par value (in dollars per shares)				$ 0.001	$ 0.001
Exercise price (in dollars per shares)				$ 0.005
Subsequent Event [Member]
Aggregate principal amount			$ 76,068
Subsequent Event [Member] | Officer And Director [Member] | Series B Preferred Stock [Member]
Conversion of common stock (in shares)	250
Subsequent Event [Member] | Officer And Director [Member] | Common Stock [Member]
Conversion of common stock (in shares)	29,969,648
Subsequent Event [Member] | Convertible 2019 Notes [Member]
Aggregate principal amount		$ 500,000
Common Stock par value (in dollars per shares)		$ 0.001
Conversion price		$ 0.015
Interest rate		7.00%
Subsequent Event [Member] | Convertible 2019 Notes [Member] | Warrant [Member]
Aggregate principal amount		$ 12,500,000
Exercise price (in dollars per shares)		$ 0.01